



## THE PREVALENCE OF CUTANEOUS ASPERGILLOSIS IN AN IMMUNOCOMPROMISED PATIENTS

T.V. Siddhartha Reddy<sup>1\*</sup>, T. Mohanalakshmi<sup>2</sup>

<sup>1</sup>Assistant Professor, Department of Community Medicine, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry, 605502, affiliated to Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu 600126, India.

<sup>2</sup>Assistant Professor, Department of Microbiology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry, 605502, affiliated to Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu 600126, India.

### Abstract

Back ground: Primary cutaneous aspergillosis in immunocompromised patients has been well described in extensive investigations. Though in immunocompetent hosts, primary cutaneous infection of aspergillus occurs rarely and residue poorly characterized in connected with Aspergillosis. This aim of the study the prevalence of cutaneous aspergillosis in an immunocompromised patient. Material methods: Cutaneous aspergillosis” was conducted March 16, 2021. Only patient history that provided the subsequent in order were integrated in this examination: patient baseline distinctiveness such as age, sex, underlying condition evidence of confirmed PCA. Results: Out of 120 patients were 82 male (68.3%). The mean was 29.4, ± 30. Ages ranged from infants to 81 years. The most popular of patients were adults from between 18 and 65 years of age. An array of underlying situation were encountered, the most frequent being blood malignancy (87.5%), followed by HIV/ AIDS (32.5%) and neonatal status (23.3%). Here 13.3%A of cases were reported with no diagnosed risk factors. Conclusion: Primary cutaneous aspergillosis may possibly arise in immunocompetent hosts. The preliminary lesions may come out in dissimilar forms such as macules, papules, nodules, and oplaques. Repeated biopsy, both culture and histopathology is considered necessary.

**Keywords:** Aspergillus fumigatus, cutaneous aspergillosis, immunocompetent.

### INTRODUCTION

Frequently, primary cutaneous aspergillosis (PCA) mainly involved in sites of skin injury specifically in the burns, surgery, at sites of traumatic inoculation and at sites connected with occlusive dressings and at intravenous access catheter sites. This is in distinguish to secondary cutaneous aspergillosis, the more familiar form, which includes the hematogenous spread of Aspergillus infection.[1] Who are severe debilitating illnesses and immunocompromised states with neutropenia are at risk for cutaneous aspergillosis and also those who are receiving long-term corticosteroids, antibiotic and cytotoxic drugs and also occurs in patients suffering from malignancies, tuberculosis, silicosis and diabetes.

Aspergillus is a ubiquitous mold instead of among 0.1% and 22% of the total air spores sampled. There are

about 250 species of Aspergillus, but only a few are human pathogens[2]. The most common human pathogens are A. fumigatus, A. flavus, and A. niger. Mainly A. fumigatus causes more than 80% of cases of Allergic bronchopulmonary aspergillosis (ABPA).

Therefore, because of the shortage of the infection. The patient characteristics, rates of disease repetition, spreading, and mortality are assigned. We undertook an analysis of the epidemiological, clinical, diagnostic, and therapeutic aspects of this serious infection with particular emphasis on the underlying condition, associated species of Aspergillus, primary management strategy, and rates of reappearance, distribution and humanity. The aim of present study was Prevalence of cutaneous aspergillosis in an immunocompromise patients.

**MATERIAL AND METHODS**

In present study “primary Cutaneous aspergillosis” was conducted March 16, 2015. Only patient history that provided the subsequent in order were integrated in this examination: patient baseline distinctiveness such as age, sex, underlying condition evidence of confirmed PCA4there is no symptom of primary infection at another site, primary treatment strategy and also patient affect mortality in immunocompromised patients, a multivariate linear regression model was built with the inclusion of all variables that had  $P < 0.2$  in univariate investigation [5]

**RESULTS**

Out of 120 patients was 82 male (68.3%). The mean was  $29.4 \pm 30$ . Ages ranged from infants to 81 years. The most popular of patients were adults from between 18 and 65 years of age. A array of underlying situation were encountered, the most frequent being blood malignancy

(87.5%), followed by HIV/ AIDS (32.5%) and neonatal status (23.3%). Here 13.3% A of cases were reported with no diagnosed risk factors.

Additional risk factors integrated solid organ transplantation (10.8%), burns (10%), corticosteroid use (7.5%), SCT (5.8%), diabetes mellitus and trauma (5% each). In the 3 patients with diabetes, poor control was suggested5 in 64 of 120 cases (53.3%), the infection was noted to be associated with a foreign body.

In the seven adults with no diagnosed immunodeficiencies and there is no risk factors, occupational information was provided in 5 of 10 cases. Four of these patients were agricultural workers6and one was a researcher in a laboratory studying Aspergillus infection. This Infection was noted to be preceded by minor trauma in 3 of 10 of these cases[7]. Outcomes appear to be linked with specific patient characteristics. [Table 1].

**Table 1: Characteristic of patients with PCA**

CHARACTERISTIC	PATIENTS
<b>sex</b>	
MALE	82(68.3%)
FEMALE	45(37.5%)
<b>Age</b>	
<1	15(12.5%)
1-20	24(20%)
21-65	85(70.8%)
>67	9(7.5%)
<b>Systemic underlying condition</b>	
Blood Malignancy	105(87.5%)
HIV	39(32.5%)
Neonates	28(23.3%)
Sot	13(10.8%)
Corticosteroid	9(7.5%)
SCT	7(5.8%)
DM	6(5%)
Other	2(1.6%)
<b>Local underlying condition</b>	
Burn	12(10%)
Truma	5(4.1%)
other	1(0.8%)
No diagnosied risk factor	16(13.3%)
<b>Out comes</b>	
Recurrence	12(10%)
Dissemination	25(20.8%)
Death	45(37.5%)

Out of total 105 (87.5%) identify the related species of Aspergillus was recognized. Of total of seven unique species. In one patient was showed, a co-infection with both A flavus and A terreus[8]Out of the cases in which the species was identified, the most frequently reported species were A fumigatus (40.8%), A flavus

(33.3%), and A niger (10.8%).Compared to other species, A ustus was considerably related with greater mortality (80%,  $P=0.0341$ ). Predominantly in HIV patients, it was not abnormal to have concomitant infections such as coexisting spreading such as bacterial infection(Mycobacterium tuberculosis, Escherichia coli,

Pseudomonas and Staphylococcus capitis) viral infection (cytomegalovirus), [9] parasitic

infection (Pneumocystis jirovecii) these are localized and co-infection during dissemination of PCA.

**Table 2: Associated Aspergillus species and relationships with outcomes**

Aspergillus species	All patients
<i>A fumigatus</i>	49(40.8%)
<i>A flavus</i>	40(33.3%)
<i>A niger</i>	13(10.8%)
<i>A ustus</i>	6(5%)
<i>A terreus</i>	5(4.1%)
<i>A flavus and A terreus</i>	2(1.6%)
Unspecified	20(16.6%)

The most frequent treatment approach was systemic Aspergillus active antifungal therapy without surgery (65.8%), subsequently antifungal in arrangement with surgery (25%) and also surgery alone (15%), there is no treatment (7.5%) (Table 3). Differentiate to the other treatment technique, surgery alone was radically connected

with enlarged disease reappearance (37.5%, P= 0.0022). Amalgamation of surgery and systemic Aspergillus- active antifungal therapy was notably linked with diminish mortality (12.8%, P=0.0230). there was no treatment of Patients getting had larger impermanency. (70.4%, P=0.0317).

**Table 3: Primary treatment strategy and also relationships with outcomes**

Treatment	All patients
Antifungal	79(65.8%)
Combination	30(25%)
Surgical	18(15%)
None	9(7.5%)

**DISCUSSION**

This is the most important and extra wide-ranging look at of posted PCA cases so far, composed of a hundred and twenty patients. The largest preceding database of PCA patients amassed from the literature consisted of fourteen patients and focused on underlying affected person diseases, related Aspergillus species. In the present take a look at, the age and sex distribution is steady with different massive collections of case reviews inside the literature of aspergillosis in standard.[10, 11]

Though, the amount of PCA patients among no apparent risk factors (16 of 120, 13.3%) in present study was elevated than other forms of aspergillosis such as pulmonary, sinus, cerebral and bone/joint aspergillosis. It is possible that colonization of the skin is additional familiar than other organ systems given its high exposure to environmental conidia. This is supported by our result that cases of PCA in immunocompetent patients were linked with occupation and in some cases, local trauma preceding infection. Only 40.8percent of identified isolates had been because of *A fumigatus* in our assessment of PCA (33.3percent of diagnosed isolates were *A flavus*). This is in difference to different styles of invasive aspergillosis with pulmonary, pores and skin, sinus, principal apprehensive system, and disseminated cases in 261 patients of invasive aspergillosis.[12] *A fumigatus* is the high pathogen related with pulmonary aspergillosis because of the capability of its quite smaller conidia to stay

away from pulmonary clearance. Usually PCA appear direct fungal inoculation after disruption of the epithelial barrier, [13] conidia size differences between species of *Aspergillus* might also have less relevance in growing number one skin infection. The accelerated distribution of species connected with PCA might be vital for treatment, as resistance patterns vary among species.

*A terreus* is regularly considered resistant to amphotericin B and *A ustus* has confirmed accelerated azole resistance.[14] In our study, *A ustus* was considerably related with greater transience in univariate study. However, as *A ustus* was involved in only 6 of 120 cases further research is required. Recent treatment guidelines discuss about surgical involvement and systemic antifungal therapy for Cutaneous aspergillosis. Our study, univariate study suggest that a grouping of systemic *Aspergillus*-active antifungal therapy and surgery was related with notably less mortality and no treatment at all was associated with significantly greater mortality . PCA often results in a necrotic lesion, and *Aspergillus* has been demonstrated to both destroy blood vessels and mitigate host angiogenesis and wound healing[15].

**CONCLUSION**

As PCA is a condition connected with extensive morbidity and mortality. Most important rates of disease reappearance and dissemination in a heterogeneous group of patients with varying degrees of immune suppression

and close attention should be paid to lesions that do not respond to antibacterial treatments, and clinicians should remain alert to the possibility of *Aspergillus* infection even in an immunocompetent patient. Consequent biopsy for microbiology and pathology is acceptable for a deep-rooted diagnosis.

#### Conflicts of interest

The authors declared no conflict of interest.

#### REFERENCE:

1. Van Burik J-AH, Colven R, Spach DH, *et al.* Cutaneous aspergillosis. *J Clin Microbiol.* 36, 1998, 3115–21.
2. Agarwal R. Allergic bronchopulmonary aspergillosis. *Chest.* 135, 2009, 805–26.
3. Walsh TJ, Anaissie EJ, Denning DW, *et al.* Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 46, 2008, 327–60.
4. Roden MM, Zaoutis TE, Buchanan WL, *et al.* Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis* 41, 2005, 634–53.
5. Nagarkar KM, Dey AB, Ray R, *et al.* Prolonged pyrexia in a diabetic due to systemic aspergillosis. *J Assoc Physicians India* 45, 1997, 887–8.
6. Sharma S, Yenigalla BM, Naidu SK, *et al.* Primary Cutaneous aspergillosis due to *Aspergillus tamarii* in an immunocompetent host. *BMJ Case Rep* 2013, 2013, 010128.
7. Tahir C, Garbati M, Ngada HA, *et al.* Primary cutaneous aspergillosis in an immunocompetent patient. *J Surg Tech Case Rep* 3, 2011, 94–6.
8. Tak V, Mathur P, Xess I, *et al.* A case of dual infection in a paediatric trauma victim of primary cutaneous aspergillosis caused by *Aspergillus flavus* and *Aspergillus terreus*. *Indian J Med Microbiol* 31, 2013, 193–6.
9. Hunt SJ, Nagi C, Gross KG, *et al.* Primary cutaneous aspergillosis near central venous catheters in patients with the acquired immunodeficiency syndrome. *Arch Dermatol* 128, 1992, 1229–32.
10. Lin S-J, Schranz J, Teutsch SM, *et al.* Aspergillosis case-fatality rate: systematic review of the literature. *Clin Infect Dis* 32, 2001, 358–66.
11. Gabrielli E, Fothergill A, Brescini L, *et al.* Osteomyelitis caused by *Aspergillus* species: a review of 310 reported cases. *Clin Microbiol Infect.* 20, 2014, 559–65.
12. Patterson TF, Kirkpatrick WR, White M, *et al.* Invasive aspergillosis disease spectrum, treatment practices, and outcomes. *Medicine* 79, 2000, 250–60.
13. Mullins J, Seaton A, *et al.* Fungal spores in lung and sputum. *Clin Exp Allergy* 8, 1978, 525–33.
14. Balajee SA, Houbraken J, Verweij PE, *et al.* *Aspergillus* species identification in the clinical setting. *Stud Mycol* 59, 2007, 39–46.
15. Ben-Ami R, Lewis RE, Leventakos K, *et al.* *Aspergillus fumigatus* inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. *Blood* 114, 2009, 5393–9.

#### Compliance With Ethics Requirements

This article does not contain any studies with human or animal subjects.

#### ACKNOWLEDGMENTS

Authors of this study wish to thank the Dean, Sree Balaji Medical College And Hospital, Chromepet for providing research laboratory.